ALBBY: AI 评分 46/100 — AI 分析 (4月 2026)

Alibaba Health Information Technology Limited operates as a healthcare and digital services provider in Mainland China and Hong Kong. The company leverages its e-commerce platform and technology to offer pharmaceutical products, medical services, and healthcare solutions.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Alibaba Health Information Technology Limited is a leading healthcare company in China, providing pharmaceutical e-commerce, direct sales, and digital healthcare services. The company leverages its parent company's technology and platform to offer a comprehensive suite of healthcare solutions, including online pharmacies, medical consultations, and health management tools.

ALBBY是做什么的？

Alibaba Health Information Technology Limited, formerly known as CITIC 21CN Company Limited, rebranded in September 2014 to align with its parent company, Alibaba Group. The company operates as an investment holding entity with a focus on pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services. Its primary market is Mainland China and Hong Kong. Alibaba Health offers a wide array of products, including prescription drugs, over-the-counter medications, nutritional supplements, and medical devices, accessible through its online stores on Tmall.com and its network of offline pharmacy outlets, catering to both business-to-customer (B2C) and business-to-business (B2B) segments. The company's e-commerce platform extends its offerings to include health food, sexual health products, contact lenses, and medical and healthcare services. Alibaba Health provides medical services such as checkups, testing, consultations, and vaccinations through various digital channels like Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. Furthermore, it engages in tracking services, network hospital operations, and the provision of internet and technical services related to healthcare, including the operation of internet hospitals and asset management.

ALBBY的投资论点是什么？

Alibaba Health presents a compelling investment case due to its strategic positioning within China's rapidly expanding digital healthcare market. The company's integration with Alibaba's vast ecosystem provides a significant competitive advantage, driving user acquisition and engagement. With a P/E ratio of 31.49 and a profit margin of 5.8%, the company demonstrates profitability and growth potential. Key growth catalysts include the increasing adoption of online healthcare services in China and the expansion of Alibaba Health's service offerings. However, investors should be aware of regulatory risks and competition within the Chinese healthcare market. The company's high beta of 1.72 indicates higher volatility compared to the market.

ALBBY在哪个行业运营？

Alibaba Health operates within the rapidly growing digital healthcare market in China. This market is driven by increasing internet penetration, rising healthcare costs, and government support for online healthcare initiatives. The competitive landscape includes both domestic players and international companies seeking to capitalize on the growing demand for digital healthcare solutions. Alibaba Health benefits from its affiliation with Alibaba Group, which provides a vast ecosystem of users and technology infrastructure. The company competes with other online pharmacies and healthcare platforms, such as JD Health and Ping An Good Doctor.

Medical - Pharmaceuticals

Healthcare

ALBBY有哪些增长机遇？

Expansion of Online Pharmacy Business: The increasing adoption of online pharmacies in China presents a significant growth opportunity for Alibaba Health. As consumers become more comfortable purchasing prescription drugs and healthcare products online, Alibaba Health can leverage its e-commerce platform and logistics network to capture a larger share of the market. The Chinese online pharmacy market is projected to reach $50 billion by 2028, offering substantial growth potential.
Development of Digital Healthcare Services: Alibaba Health can further expand its digital healthcare services, such as online consultations, remote monitoring, and chronic disease management. These services address the growing demand for convenient and accessible healthcare solutions. The digital healthcare market in China is expected to reach $200 billion by 2027, driven by government support and increasing consumer adoption.
Strategic Partnerships with Hospitals and Clinics: Collaborating with hospitals and clinics to integrate online and offline healthcare services can enhance Alibaba Health's service offerings and expand its reach. These partnerships can enable the company to provide a more comprehensive and integrated healthcare experience for patients. The market for integrated healthcare solutions is growing rapidly, driven by the need for more efficient and coordinated care.
Leveraging Artificial Intelligence and Big Data: Utilizing AI and big data analytics to personalize healthcare recommendations, improve diagnosis accuracy, and optimize treatment plans can enhance the value of Alibaba Health's services. These technologies can also help the company identify emerging health trends and develop innovative solutions. The AI in healthcare market is projected to reach $34 billion by 2025, offering significant opportunities for innovation and growth.
Geographic Expansion within China: Expanding its presence in Tier 2 and Tier 3 cities in China can enable Alibaba Health to reach a wider customer base and tap into underserved markets. These cities are experiencing rapid economic growth and increasing demand for healthcare services. The healthcare market in Tier 2 and Tier 3 cities is expected to grow at a faster rate than in Tier 1 cities, presenting a significant growth opportunity.

Market capitalization of $12.50 billion, reflecting substantial investor confidence in the company's market position.
P/E ratio of 31.49, indicating a premium valuation based on earnings, suggesting strong growth expectations.
Profit margin of 5.8%, demonstrating the company's ability to generate profit from its revenue streams.
Gross margin of 24.5%, reflecting the efficiency of its operations in managing the cost of goods sold.
Beta of 1.72, indicating higher volatility compared to the market, which may appeal to risk-tolerant investors seeking higher returns.

ALBBY提供哪些产品和服务？

Operates online pharmacies selling prescription and over-the-counter drugs.
Provides medical and healthcare services through digital channels.
Offers health-related products, including nutritional supplements and medical devices.
Manages an e-commerce platform for healthcare products and services.
Engages in pharmaceutical direct sales to businesses and consumers.
Provides tracking services for pharmaceutical products.
Operates internet hospitals and provides related technical services.

ALBBY如何赚钱？

Generates revenue through the sale of pharmaceutical products and healthcare services on its online platforms.
Earns commissions from third-party vendors selling products on its e-commerce platform.
Provides subscription-based healthcare services to consumers and businesses.
Offers advertising and marketing services to healthcare companies.

Individual consumers seeking pharmaceutical products and healthcare services.
Hospitals and clinics purchasing pharmaceutical products and healthcare solutions.
Businesses offering healthcare benefits to their employees.
Healthcare companies seeking to market their products and services.

Strong brand recognition and reputation in the Chinese healthcare market.
Integration with Alibaba's vast ecosystem of users and technology infrastructure.
Extensive network of online and offline pharmacies.
Proprietary technology and data analytics capabilities.

什么因素可能推动ALBBY股价上涨？

Ongoing: Expansion of online pharmacy business driven by increasing internet penetration in China.
Ongoing: Development of digital healthcare services, including online consultations and remote monitoring.
Upcoming: Potential regulatory changes in China that could favor online healthcare platforms.
Ongoing: Strategic partnerships with hospitals and clinics to integrate online and offline services.

ALBBY的主要风险是什么？

Potential: Changes in government regulations regarding online pharmacies and healthcare services.
Ongoing: Increased competition from other online healthcare platforms and traditional pharmacies.
Potential: Data security and privacy concerns related to the collection and use of patient data.
Potential: Economic slowdown in China that could impact consumer spending on healthcare products and services.

ALBBY的核心优势是什么？

Strong brand recognition and reputation.
Integration with Alibaba's ecosystem.
Extensive online and offline network.
Proprietary technology and data analytics.

ALBBY的劣势是什么？

Reliance on Alibaba's ecosystem.
Exposure to regulatory risks in China.
Competition from other online healthcare platforms.
Relatively low profit margin.

ALBBY有哪些机遇？

Expansion of online pharmacy business.
Development of digital healthcare services.
Strategic partnerships with hospitals and clinics.
Leveraging AI and big data analytics.

ALBBY面临哪些威胁？

Changes in government regulations.
Increased competition from domestic and international players.
Data security and privacy concerns.
Economic slowdown in China.

ALBBY的竞争对手是谁？

Bayer AG — Global pharmaceutical and healthcare company with a presence in China. — (BDUUY)
Beiersdorf AG — German personal-care company with a focus on skincare and healthcare products. — (BMXMF)
China Traditional Chinese Medicine Holdings Co Ltd — Chinese company focused on traditional Chinese medicine products. — (CHEOF)
China Traditional Chinese Medicine Holdings Co Ltd — Chinese company focused on traditional Chinese medicine products. — (CHEOY)
China Jo-Jo Drugstores Inc — Chinese drugstore chain offering pharmaceutical products and healthcare services. — (CHJTF)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Difan Shen
Headquarters: Causeway Bay, HK
Employees: 1,422
Founded: 2019

AI Insight

AI analysis pending for ALBBY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: ALBB

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Alibaba Health Information Technology Limited do?

Alibaba Health Information Technology Limited operates as a healthcare and digital services provider, primarily in Mainland China and Hong Kong. The company focuses on pharmaceutical direct sales, operating a pharmaceutical e-commerce platform, and delivering various healthcare and digital services. It offers a wide range of products, including prescription and over-the-counter drugs, nutritional supplements, and medical devices, through its online stores on Tmall.com and offline pharmacies. Additionally, the company provides medical services like checkups, consultations, and vaccinations via digital channels, leveraging its parent company's technology and platform to offer comprehensive healthcare solutions.

What do analysts say about ALBBY stock?

AI analysis is currently pending for ALBBY. Therefore, a neutral summary of analyst consensus, key valuation metrics, and growth considerations is unavailable at this time. Investors should consult with a financial advisor and conduct their own due diligence before making any investment decisions. Further information will be available once the AI analysis is complete.

What are the main risks for ALBBY?

Alibaba Health faces several risks, including regulatory changes in China affecting online pharmacies and healthcare services. Increased competition from both domestic and international players in the digital healthcare market poses a threat. Data security and privacy concerns related to patient data are also significant. An economic slowdown in China could impact consumer spending on healthcare products and services, affecting the company's revenue and profitability.